Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai

• Main Authors: Jiaming Gao (Author), Taiyi Wang (Author), Xi Yao (Author), Weiwei Xie (Author), Xianru Shi (Author), Shuang He (Author), Tao Zhao (Author), Chunhua Wang (Author), Yan Zhu (Author)
• Format: Book
• Published: BMC, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy...